Twist Bioscience Corporation (TWST) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
7.40
↑+66% vs avg
5yr avg: 4.45
30Y Low1.8·High8.9
ROE
↑
-16.4%
↓+45% vs avg
5yr avg: -29.7%
30Y Low-71%·High-16%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TWST Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Twist Bioscience Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.6B | $1.7B | $2.6B | $1.2B | $1.9B | $5.2B | $3.0B | $656M | — | — | — |
| Enterprise Value | $3.6B | $1.6B | $2.5B | $960M | $1.6B | $4.8B | $2.9B | $617M | — | — | — |
| P/E Ratio → | -45.03 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 9.68 | 4.47 | 8.38 | 4.70 | 9.33 | 39.00 | 33.04 | 12.06 | — | — | — |
| P/B Ratio | 7.40 | 3.56 | 5.55 | 1.85 | 2.41 | 8.89 | 8.85 | 4.31 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TWST EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.35 | 7.92 | 3.92 | 7.93 | 35.96 | 32.40 | 11.34 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
TWST Profitability
Margins and return-on-capital ratios measuring operating efficiency
Twist Bioscience Corporation earns an operating margin of -36.2%. Operating margins have expanded from -88.6% to -36.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -16.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 50.7% | 50.7% | 42.6% | 36.6% | 41.4% | 39.1% | 31.8% | 12.8% | -26.6% | -123.1% | -315.2% |
| Operating Margin | -36.2% | -36.2% | -70.6% | -88.6% | -115.3% | -115.4% | -155.5% | -200.1% | -277.5% | -543.2% | -1924.0% |
| Net Profit Margin | -20.6% | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | -155.3% | -198.0% | -280.2% | -550.8% | -1943.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.4% | -16.4% | -38.1% | -29.0% | -31.8% | -33.2% | -57.3% | -70.8% | — | — | — |
| ROA | -12.4% | -12.4% | -30.0% | -23.5% | -26.2% | -27.6% | -47.8% | -71.1% | -70.7% | -73.2% | -57.7% |
| ROIC | -26.9% | -26.9% | -43.4% | -34.8% | -51.5% | -50.2% | -53.6% | -72.2% | — | — | — |
| ROCE | -24.9% | -24.9% | -35.4% | -27.6% | -31.1% | -30.5% | -53.9% | -85.7% | -81.4% | -81.2% | -64.4% |
TWST Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $183M exceeds total debt of $137M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.29 | 0.29 | 0.18 | 0.15 | 0.12 | 0.11 | 0.11 | 0.05 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.10 | -0.30 | -0.31 | -0.36 | -0.69 | -0.17 | -0.26 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -7177.14 | -40692.20 | -2852.43 | -418.69 | -176.32 | -81.98 | -53.07 | -64.23 | -58.10 |
Net cash position: cash ($183M) exceeds total debt ($137M)
TWST Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Twist Bioscience Corporation's current ratio of 3.64x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.33x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.79x to 3.64x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.64 | 3.64 | 4.88 | 5.79 | 6.58 | 8.67 | 9.29 | 5.28 | 5.16 | 7.16 | 6.80 |
| Quick Ratio | 3.33 | 3.33 | 4.54 | 5.35 | 6.15 | 8.16 | 8.95 | 5.03 | 4.84 | 6.97 | 6.66 |
| Cash Ratio | 2.54 | 2.54 | 3.89 | 4.59 | 5.57 | 7.58 | 8.05 | 4.55 | 4.36 | 6.56 | 6.44 |
| Asset Turnover | — | 0.59 | 0.51 | 0.32 | 0.21 | 0.19 | 0.23 | 0.29 | 0.22 | 0.13 | 0.03 |
| Inventory Turnover | 6.56 | 6.56 | 7.46 | 4.85 | 3.04 | 2.54 | 5.00 | 6.47 | 5.34 | 13.15 | 7.67 |
| Days Sales Outstanding | — | 55.27 | 40.70 | 65.62 | 72.25 | 78.74 | 103.00 | 81.23 | 77.79 | 79.53 | 116.30 |
TWST Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Twist Bioscience Corporation returns 0.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.2% | 0.4% | 0.4% | 0.2% | 0.1% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.2% | 0.4% | 0.4% | 0.2% | 0.1% | 0.0% | — | — | — |
| Shares Outstanding | — | $60M | $58M | $57M | $54M | $48M | $39M | $27M | $27M | $19M | $19M |
Peer Comparison
Compare TWST with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TWSTYou | $4B | -45.0 | — | — | 50.7% | -36.2% | -16.4% | -26.9% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 PACB | $498M | -0.9 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 GH | $12B | -27.8 | — | — | 64.5% | -44.4% | — | -34.9% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 CDNA | $1B | -53.6 | — | 30.7 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 NTRA | $31B | -144.6 | — | 285.5 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 FLGT | $449M | -7.7 | — | — | 40.6% | -28.2% | -5.4% | -6.4% | — |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
See TWST's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TWST Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TWST vs ILMN
Side-by-side business, growth, and profitability comparison vs Illumina, Inc..
Start ComparisonTWST — Frequently Asked Questions
Quick answers to the most common questions about buying TWST stock.
What is Twist Bioscience Corporation's P/E ratio?
Twist Bioscience Corporation's current P/E ratio is -45.0x. This places it at the 50th percentile of its historical range.
What is Twist Bioscience Corporation's ROE?
Twist Bioscience Corporation's return on equity (ROE) is -16.4%. The historical average is -39.5%.
Is TWST stock overvalued?
Based on historical data, Twist Bioscience Corporation is trading at a P/E of -45.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Twist Bioscience Corporation's profit margins?
Twist Bioscience Corporation has 50.7% gross margin and -36.2% operating margin.